vs

Side-by-side financial comparison of CHEGG, INC (CHGG) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.

4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $72.7M, roughly 1.2× CHEGG, INC). On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -49.4%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-15.5M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -35.4%).

Chegg, Inc., is an American educational technology company based in Santa Clara, California. It provides homework help, digital and physical textbook rentals, textbooks, online tutoring, and other student services, powered by artificial intelligence. The company has 6.6 million subscribers. Chegg has been widely criticized for facilitating cheating and academic dishonesty among students.

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

CHGG vs FDMT — Head-to-Head

Bigger by revenue
FDMT
FDMT
1.2× larger
FDMT
$85.1M
$72.7M
CHGG
Growing faster (revenue YoY)
FDMT
FDMT
+8508949.4% gap
FDMT
8508900.0%
-49.4%
CHGG
More free cash flow
FDMT
FDMT
$44.0M more FCF
FDMT
$28.5M
$-15.5M
CHGG
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-35.4%
CHGG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CHGG
CHGG
FDMT
FDMT
Revenue
$72.7M
$85.1M
Net Profit
$19.4M
Gross Margin
57.3%
Operating Margin
-47.2%
17.3%
Net Margin
22.8%
Revenue YoY
-49.4%
8508900.0%
Net Profit YoY
139.1%
EPS (diluted)
$-0.30
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHGG
CHGG
FDMT
FDMT
Q4 25
$72.7M
$85.1M
Q3 25
$77.7M
$90.0K
Q2 25
$105.1M
$15.0K
Q1 25
$121.4M
$14.0K
Q4 24
$143.5M
$1.0K
Q3 24
$136.6M
$3.0K
Q2 24
$163.1M
$5.0K
Q1 24
$174.3M
$28.0K
Net Profit
CHGG
CHGG
FDMT
FDMT
Q4 25
$19.4M
Q3 25
$-17.5M
$-56.9M
Q2 25
$-35.7M
$-54.7M
Q1 25
$-17.5M
$-48.0M
Q4 24
Q3 24
$-212.6M
$-43.8M
Q2 24
$-616.9M
$-35.0M
Q1 24
$-1.4M
$-32.4M
Gross Margin
CHGG
CHGG
FDMT
FDMT
Q4 25
57.3%
Q3 25
59.2%
Q2 25
66.3%
Q1 25
55.5%
Q4 24
68.2%
Q3 24
68.2%
Q2 24
72.2%
Q1 24
73.3%
Operating Margin
CHGG
CHGG
FDMT
FDMT
Q4 25
-47.2%
17.3%
Q3 25
-22.0%
-67983.3%
Q2 25
-34.7%
-396373.3%
Q1 25
-23.9%
-383007.1%
Q4 24
-19.0%
Q3 24
-162.7%
-1704400.0%
Q2 24
-297.3%
-849120.0%
Q1 24
-1.4%
-136200.0%
Net Margin
CHGG
CHGG
FDMT
FDMT
Q4 25
22.8%
Q3 25
-22.5%
-63195.6%
Q2 25
-33.9%
-364386.7%
Q1 25
-14.4%
-342657.1%
Q4 24
Q3 24
-155.7%
-1461433.3%
Q2 24
-378.1%
-699060.0%
Q1 24
-0.8%
-115717.9%
EPS (diluted)
CHGG
CHGG
FDMT
FDMT
Q4 25
$-0.30
$0.43
Q3 25
$-0.16
$-1.01
Q2 25
$-0.33
$-0.98
Q1 25
$-0.17
$-0.86
Q4 24
$-0.03
Q3 24
$-2.05
$-0.79
Q2 24
$-6.01
$-0.63
Q1 24
$-0.01
$-0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHGG
CHGG
FDMT
FDMT
Cash + ST InvestmentsLiquidity on hand
$72.8M
$402.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$119.6M
$505.7M
Total Assets
$278.0M
$566.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHGG
CHGG
FDMT
FDMT
Q4 25
$72.8M
$402.7M
Q3 25
$96.4M
$305.1M
Q2 25
$85.6M
$293.2M
Q1 25
$88.3M
$321.4M
Q4 24
$315.7M
$424.9M
Q3 24
$361.1M
$501.9M
Q2 24
$345.5M
$541.9M
Q1 24
$390.8M
$525.9M
Stockholders' Equity
CHGG
CHGG
FDMT
FDMT
Q4 25
$119.6M
$505.7M
Q3 25
$146.1M
$369.0M
Q2 25
$157.9M
$420.9M
Q1 25
$185.7M
$469.7M
Q4 24
$193.0M
$510.6M
Q3 24
$185.0M
$552.9M
Q2 24
$365.5M
$588.3M
Q1 24
$963.5M
$600.6M
Total Assets
CHGG
CHGG
FDMT
FDMT
Q4 25
$278.0M
$566.7M
Q3 25
$378.3M
$424.0M
Q2 25
$404.5M
$473.6M
Q1 25
$438.8M
$515.7M
Q4 24
$869.0M
$560.4M
Q3 24
$1.0B
$604.0M
Q2 24
$1.1B
$620.1M
Q1 24
$1.7B
$629.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHGG
CHGG
FDMT
FDMT
Operating Cash FlowLast quarter
$-9.0M
$28.6M
Free Cash FlowOCF − Capex
$-15.5M
$28.5M
FCF MarginFCF / Revenue
-21.3%
33.5%
Capex IntensityCapex / Revenue
8.9%
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-12.6M
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHGG
CHGG
FDMT
FDMT
Q4 25
$-9.0M
$28.6M
Q3 25
$4.8M
$-46.5M
Q2 25
$-4.8M
$-43.4M
Q1 25
$24.5M
$-47.8M
Q4 24
$18.1M
$-134.6M
Q3 24
$39.5M
$-29.4M
Q2 24
$14.2M
$-30.2M
Q1 24
$53.3M
$-29.1M
Free Cash Flow
CHGG
CHGG
FDMT
FDMT
Q4 25
$-15.5M
$28.5M
Q3 25
$-943.0K
$-46.6M
Q2 25
$-12.1M
$-43.4M
Q1 25
$15.9M
$-48.4M
Q4 24
$4.8M
$-138.4M
Q3 24
$23.7M
$-31.2M
Q2 24
$-3.6M
$-30.6M
Q1 24
$25.3M
$-29.8M
FCF Margin
CHGG
CHGG
FDMT
FDMT
Q4 25
-21.3%
33.5%
Q3 25
-1.2%
-51765.6%
Q2 25
-11.5%
-289620.0%
Q1 25
13.1%
-345635.7%
Q4 24
3.4%
-13837100.0%
Q3 24
17.3%
-1038966.7%
Q2 24
-2.2%
-611840.0%
Q1 24
14.5%
-106421.4%
Capex Intensity
CHGG
CHGG
FDMT
FDMT
Q4 25
8.9%
0.1%
Q3 25
7.4%
101.1%
Q2 25
6.9%
440.0%
Q1 25
7.1%
4507.1%
Q4 24
9.3%
378600.0%
Q3 24
11.6%
59266.7%
Q2 24
10.9%
6980.0%
Q1 24
16.1%
2535.7%
Cash Conversion
CHGG
CHGG
FDMT
FDMT
Q4 25
1.47×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons